Highlights Takeda Pharmaceutical Company Limited

Stocks

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-07-15 EDT			5-day change	1st Jan Change
5,288.00 ^JPY	-0.73%		-2.94%	+9.37%

10:23pm	Taiwan's Bora Pharmaceuticals in potential $2.5 billion collaboration with Insilico Medicine	RE
07-13	Takeda, Indonesian Government Launch Program to Build National Plasma Ecosystem	MT

Highlights

07-13	Takeda, Indonesian Government Launch Program to Build National Plasma Ecosystem	MT
07-12	Takeda Pharmaceutical Company Limited and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products	CI
07-01	Insilico Medicine Strikes Drug Discovery Deal With Japan's Takeda Pharmaceutical	MT
06-24	Takeda Pharmaceutical Company Limited Announces Dividend Payment	CI
06-15	Takeda Pharmaceutical Company Limited Presents Additional Results from Two Pivotal Studies Showing Oveporexton Improves Daily Function, Cognition, and Nighttime Sleep for People with Narcolepsy Type 1	CI
06-11	Takeda Announces Positive Topline Results for Phase 3 Study Comparing Zasocitinib to Deucravacitinib in Adults with Moderate-To-Severe Plaque Psoriasis	CI
06-05	Takeda Books $2.5 Billion Provision Related to Amitiza Antitrust Litigation	DJ
05-19	Takeda Pharmaceutical Found Liable in Constipation Drug Antitrust Case	MT
05-19	Takeda Pharmaceutical Reportedly Found Liable in Constipation Drug Antitrust Case	MT
05-18	US Jury Orders Takeda to Pay $885 Million in AMITIZA Antitrust Case; Takeda Plans Appeal	MT
05-18	Takeda pharmaceutical - currently assessing amount of provision to be recognized in group earnings for FY ended March 31	RE
05-18	Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds	RE
05-18	Jury Orders Takeda to Pay Hundreds of Millions in Antitrust Case, Bloomberg Reports	MT
05-13	Takeda Pharmaceutical's Profit Soars 78% in Fiscal Year 2025	MT
05-13	Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit	DJ
05-13	Takeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook	MT
05-13	Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Full Year Fiscal Year 2026	CI
05-13	Takeda Pharmaceutical Company Limited Proposes Annual Dividend for Fiscal Year 2025	CI
05-13	Takeda Pharmaceutical Company Limited Proposes Dividend for the Year-End of Fiscal Year Ended March 31, 2026, Payable on June 25, 2026; Provides Dividend Guidance for the Second Quarter End and Year-End of Fiscal Year Ending March 31, 2027	CI
05-13	Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI
05-12	Takeda Pharmaceutical Company Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
05-04	Takeda's next-gen experimental immune drug comparable to approved treatment in study	RE
05-04	Takeda Pharmaceutical Company Limited Announces Positive Topline Results From Pivotal Phase 2/3 Clinical Trial Of TAK-881 In Primary Immunodeficiency Disease	CI
04-27	Intellia's gene therapy for rare disease cuts swelling attacks in late-stage trial	RE
04-13	Spyre's inflammatory bowel drug reduces disease activity in mid-stage study	RE